Aurobindo Pharma receives FDA approval for Dolutegravir, Lamivudine & Tenofovir Disoproxil tablets
Aurobindo Pharma Limited is pleased to announce that the company has received tentative approval from the U.S. FDA under the...
Strategic Collaboration Agreement to Co-Develop Multiple Novel Biologic Therapies signed by Samsung Bioepis And Takeda
Samsung Bioepis Co., Ltd. announced that it has entered into a strategic collaboration agreement with Takeda Pharmaceutical Company Limited to...
Astellas Pharma begins phase 3 MORPHO trial of gilteritinib as maintenance therapy with FLT3 mutation-positive AML
Astellas Pharma Inc. announced that the first patient was dosed in the registrational Phase 3 MORPHO trial of gilteritinib, the...
Ritter Pharmaceuticals Announces Phase 3 Plans after its End of Phase 2 Meeting with FDA on RP-G28 for Lactose Intolerance
Ritter Pharmaceuticals, a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced...
Aurobindo Pharma receives USFDA Approval for Sevela mer Carbonate tablets
Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug...
Alvogen Announces Acquisition to Expand Russian Business
Alvogen announced today that it has signed a definitive agreement to acquire Omega Bittner, a Russia-based pharmaceutical firm owned by...
Bristol-Myers Squibb reports positive results from CheckMate -214 phase 3 study of Opdivo
Bristol-Myers Squibb Company announced topline results from the CheckMate -214 trial investigating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) versus...
A New Drug Research And Development Cooperation Reached By Chengdu Pilot And Aduro
Chengdu Pioneer Drug Development Co., Ltd. announced a multi-year, long-term, new drug research and development collaboration with Aduro Biotech to...
CARsgen Launches First-in-Class Anti-Claudin18.2 CAR-T Clinical Trial
CARsgen Therapeutics (CARsgen), a global leader in developing chimeric antigen receptor T-cell (CAR-T cell) therapies for solid tumors announced its...
Motif Bio’s second Phase 3 clinical trial in ABSSSI finishes patient treatment phase
Motif Bio plc ,the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced that the last patient has completed...
Latest News
About Us
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.